Polymorphism of human cytochrome P450 enzymes and its clinical impact.
Pharmacogenetics is the study of how interindividual variations in the DNA sequence of specific genes affect drug response. This article highlights current pharmacogenetic knowledge on important human drug-metabolizing cytochrome P450s (CYPs) to understand the large interindividual variability in drug clearance and responses in clinical practice. The human CYP superfamily contains 57 functional genes and 58 pseudogenes, with members of the 1, 2, and 3 families playing an important role in the metabolism of therapeutic drugs, other xenobiotics, and some endogenous compounds. Polymorphisms in the CYP family may have had the most impact on the fate of therapeutic drugs. CYP2D6, 2C19, and 2C9 polymorphisms account for the most frequent variations in phase I metabolism of drugs, since almost 80% of drugs in use today are metabolized by these enzymes. Approximately 5-14% of Caucasians, 0-5% Africans, and 0-1% of Asians lack CYP2D6 activity, and these individuals are known as poor metabolizers. CYP2C9 is another clinically significant enzyme that demonstrates multiple genetic variants with a potentially functional impact on the efficacy and adverse effects of drugs that are mainly eliminated by this enzyme. Studies into the CYP2C9 polymorphism have highlighted the importance of the CYP2C9*2 and *3 alleles. Extensive polymorphism also occurs in other CYP genes, such as CYP1A1, 2A6, 2A13, 2C8, 3A4, and 3A5. Since several of these CYPs (e.g., CYP1A1 and 1A2) play a role in the bioactivation of many procarcinogens, polymorphisms of these enzymes may contribute to the variable susceptibility to carcinogenesis. The distribution of the common variant alleles of CYP genes varies among different ethnic populations. Pharmacogenetics has the potential to achieve optimal quality use of medicines, and to improve the efficacy and safety of both prospective and currently available drugs. Further studies are warranted to explore the gene-dose, gene-concentration, and gene-response relationships for these important drug-metabolizing CYPs.
Zhou
Shu-Feng
SF
School of Health Sciences, RMIT University, Bundoora, Victoria, Australia. shufeng.zhou@rmit.edu.au
Liu
Jun-Ping
JP
Chowbay
Balram
B
D000483:Alleles; D000818:Animals; D001564:Benzo(a)pyrene / Q000737:chemistry / Q000378:metabolism; D002874:Chromosome Mapping; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics* / Q000378:metabolism; D004790:Enzyme Induction; D005006:Ethnicity / Q000235:genetics; D020022:Genetic Predisposition to Disease; D006801:Humans; D007527:Isoenzymes / Q000235:genetics* / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D015394:Molecular Structure; D009369:Neoplasms / Q000235:genetics; D004364:Pharmaceutical Preparations / Q000378:metabolism; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D013379:Substrate Specificity
D007527:Isoenzymes; D004364:Pharmaceutical Preparations; D001564:Benzo(a)pyrene; D003577:Cytochrome P-450 Enzyme System